Cytokine profiling identifies circulating IL-2, IL23 and sPD-L1 as prognostic biomarkers for treatment outcomes in non-small cell lung cancer patients undergoing anti-PD1 therapy
Open Access
- 8 July 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1628379
Abstract
Background: This study investigates the predictive potential of circulating cytokines for response and survival outcomes in patients with advanced non-small cell lung cancer (NSCLC) undergoing immune checkpoint inhibitor (ICI) therapy.Materials and methods: A cohort of 64 patients with advanced NSCLC receiving ICI therapy were included. Baseline serum samples were collected prior to ICI initiation and profiled using a multiplex cytokine panel. Logistic regression, Cox regression, and Kaplan-Meier survival analysis were employed to assess associations between cytokine levels, therapeutic response, progression-free survival (PFS), and overall survival (OS). Gene expression levels of key cytokines were validated in peripheral blood mononuclear cells (PBMCs) of 17 patients (Responders = 7, Non-Responders = 10) and 3 Healthy Controls using quantitative real-time PCR.Results: Elevated baseline levels of IL-2, IL-23, and sPD-L1 were significantly associated with clinical response to ICI therapy. Among these, sPD-L1 emerged as an independent predictor of response (AUC = 0.87). Multivariate Cox regression showed IL-2 (HR = 0.67), sPD-L1 (HR = 0.15), and IL-23 (HR = 1.18) were significantly associated with PFS and also predictive of OS. Notably, combined profiling of IL-2 and sPD-L1 enhanced predictive power (AUC = 0.95 for both PFS and OS). RT-PCR analysis of PBMCs corroborated these findings, confirming upregulation of IL-2 in responders and elevated IL-23 expression in non-responders.Conclusion: Baseline cytokine profiling particularly of IL-2, sPD-L1, and IL-23 provides important prognostic and predictive information in advanced NSCLC patients undergoing ICI therapy. These biomarkers may facilitate more personalized approaches to immunotherapy and guide clinical decision-making.Keywords
All Related Versions
This publication has 21 references indexed in Scilit:
- Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7BMB Reports, 2021
- Prognostic value of serum soluble interleukin‐23 receptor and related T‐helper 17 cell cytokines in non‐small cell lung carcinomaCancer Science, 2020
- Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancerJournal of Thoracic Disease, 2018
- Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung CancerJAMA Oncology, 2016
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- The Effect of Lung Cancer on Cytokine Expression in Peripheral Blood Mononuclear CellsPLOS ONE, 2013
- Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patientsLung Cancer, 2006
- Lung cancer * 4: Chemotherapy for non-small cell lung cancer: the end of the beginningThorax, 2003
- Cytokines in Patients with Lung CancerScandinavian Journal of Immunology, 2003
- The epidemiology of lung cancerAnnals of Oncology, 1999